Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 62 references it cites were found in a registry or an index; 14 of the 23 sources its claims cite were checked for support.

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

Open access

Abstract

Thirty-nine articles were included in the review showing a total number of 33,354 individuals. Nausea, vomiting, diarrhea, and constipation were the most common gastrointestinal adverse effects. All evaluated GLP-1 RAs led to a significant increase in nausea risk, with orforglipron showing the highest risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. Additionally, liraglutide, orforglipron, semaglutide, and tirzepatide were associated with increased vomiting risk, while cagrilinitide and exenatide showed no significant increase. Exenatide, cagrilinitide, orforglipron were not associated with diarrhea risk. Finally, semaglutide and liraglutide were associated to increased constipation risk, while cagrilinitide and exenatide showed no significant increase.

Overview

CoChat Summary

## TL;DR

This systematic review and dose-response network meta-analysis included 39 articles and 33,354 non-diabetic adults with overweight or obesity to compare gastrointestinal adverse events across GLP-1 receptor agonists and related agents. All evaluated drugs increased nausea risk, while higher doses were associated with more nausea, vomiting, diarrhea, constipation, and decreased appetite.

## Key findings

  • The review included 39 articles and 33,354 individuals; the most common gastrointestinal adverse effects were nausea, vomiting, diarrhea, and constipation.
  • All evaluated GLP-1 RAs significantly increased nausea risk; the highest risk was with orforglipron (RR 4.7748, 95% CI 2.0161–11.3085), followed by liraglutide, semaglutide, tirzepatide, exenatide, and cagrilinitide.
  • Vomiting risk increased with liraglutide (RR 3.8722), orforglipron (RR 3.8722), semaglutide (RR 4.2108), and tirzepatide (RR 13.2265); cagrilinitide and exenatide were not significantly increased.
  • Diarrhea was significantly increased with semaglutide (RR 1.7714), liraglutide (RR 1.8231), and tirzepatide (RR 3.3537), while exenatide, cagrilinitide, and orforglipron were not.
  • In dose-response analyses, higher doses of GLP-1 RAs were associated with increased risks of nausea, vomiting, diarrhea, constipation, and decreased appetite, with many outcomes rising quickly at lower doses then plateauing.

## Methods

  • Design: Systematic review and dose-response network meta-analysis, conducted according to PRISMA 2020.
  • Data/sample: Searches of PubMed and EMBASE from inception to December 20, 2023; 39 interventional studies/RCTs in non-diabetic adults with overweight or obesity.
  • Analysis: Random-effects network meta-analysis using restricted maximum likelihood, with comparisons reported as RRs with 95% CIs; heterogeneity assessed with Q-test and I², and risk of bias evaluated with the Cochrane Collaboration tool.

## Limitations

  • The paper states there was significant heterogeneity in study design, populations, dose regimens, and follow-up duration, and that some trials had high risk of bias; these factors could affect reliability.
  • Some adverse events were reported in few trials (e.g., viral gastroenteritis, hard feces, infrequent bowel movements), limiting robust analyses.
  • The authors state they could not do duration-based subgroup analyses because of missing stratified time-point data, and they could not compare adult vs. elderly or pediatric/adolescent groups because included studies enrolled adults only.
  • Evident from the text: most studies came from a limited set of countries (U.S., Denmark, China, Slovenia), so generalizability may be limited; reporting/classification differences across studies may also have introduced inconsistency.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41366-025-01859-6

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA flow diagram. The PRISMA flow diagram outlining the stages of identification, screening, and inclusion.
Fig. 1 PRISMA flow diagram. The PRISMA flow diagram outlining the stages of identification, screening, and inclusion.CC BY · PubMed Central
Fig. 2 Risk of nausea, vomiting, diarrhea, and constipation in GLP-1 RAs. Forest plots regarding the risk of (A) nausea, B vomiting, C diarrhea, and D constipation in patients receiving GLP-1 RAs.
Fig. 2 Risk of nausea, vomiting, diarrhea, and constipation in GLP-1 RAs. Forest plots regarding the risk of (A) nausea, B vomiting, C diarrhea, and D constipation in patients receiving GLP-1 RAs.CC BY · PubMed Central
Fig. 3 Risk of abdominal symptoms in GLP-1 RAs. Forest plots regarding the risk of (A) abdominal distention, B abdominal pain upper, C abdominal pain, and D abdominal discomfort in patients receiving GLP-1 RAs.
Fig. 3 Risk of abdominal symptoms in GLP-1 RAs. Forest plots regarding the risk of (A) abdominal distention, B abdominal pain upper, C abdominal pain, and D abdominal discomfort in patients receiving GLP-1 RAs.CC BY · PubMed Central
Fig. 4 Risk of GERD, eructation, flatulence, and decreased appetite in GLP-1 RAs. Forest plots regarding the risk of (A) GERD, B eructation, C flatulence, and D decreased appetite in patients receiving GLP-1 RAs.
Fig. 4 Risk of GERD, eructation, flatulence, and decreased appetite in GLP-1 RAs. Forest plots regarding the risk of (A) GERD, B eructation, C flatulence, and D decreased appetite in patients receiving GLP-1 RAs.CC BY · PubMed Central
Fig. 5 Risk of gallbladder disease in GLP-1 RAs. Forest plots regarding the risk of (A) cholelithiasis, B gallstone-related, C cholecystitis, and D acute cholecystitis in patients receiving GLP-1 RAs.
Fig. 5 Risk of gallbladder disease in GLP-1 RAs. Forest plots regarding the risk of (A) cholelithiasis, B gallstone-related, C cholecystitis, and D acute cholecystitis in patients receiving GLP-1 RAs.CC BY · PubMed Central
Fig. 6 Risk of pancreatitis, gastroenteritis, and bowel movement disorders in GLP-1 RAs. Forest plot regarding the risk of (A) acute pancreatitis, B viral gastroenteritis, C feces hard, and D infrequent bowel movements in patients receiving GLP-1 RAs.
Fig. 6 Risk of pancreatitis, gastroenteritis, and bowel movement disorders in GLP-1 RAs. Forest plot regarding the risk of (A) acute pancreatitis, B viral gastroenteritis, C feces hard, and D infrequent bowel movements in patients receiving GLP-1 RAs.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 4 Not valid · 6 Not checked · 123 Own results and interpretations

88 more claims

Create a free account to see all 141 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 30

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 62 references

Research works printed but not linked: 1

  1. Zhuo-yue G, Tian-sheng W, Man-ling M, Suo-di Z. A meta-analysis of GI adverse events of GLP-1 receptor agonists and DPP-4 inhibitors. Chin Pharm J. 2014;49:935–940.

Cited by

See all 99

Metadata

Authors
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L.
Affiliations
  • Iuliu Hațieganu University of Medicine and Pharmacy (RO)
  • Magna Graecia University (IT)
Corresponding author
Leucuta, Daniel-Corneliu
Venue
International Journal of Obesity
Published
2025-08-13
Volume
49
Issue
10
Pages
1946-1957
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W4413117488
Cited by
99
References
62
Citations by year
2026: 90 · 2025: 9
FWCI
13.29
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Obesity (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, non-diabetic patients, obesity, overweight, weight loss, orforglipron, exenatide, tirzepatide, semaglutide, liraglutide, dose-response relationship
MeSH terms
Network Meta-Analysis as Topic, Glucagon-Like Peptide-1 Receptor Agonists, Gastrointestinal Diseases, Humans, Obesity, Overweight, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1038/s41366-025-01859-6
The paper
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025). Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. International Journal of Obesity. https://doi.org/10.1038/s41366-025-01859-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.